A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.
James R. Berenson(American Society of Clinical Oncology), Sal Bevivino(Oncotherapeutics (United States)), Russell Mapes(Institute for Myeloma & Bone Cancer Research), J. Matouš(Rocky Mountain Cancer Centers), Howard Yeh(Covance (United States)), Blake Morrison(Millennium Engineering and Integration (United States)), Delina Ferretti(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research)
Cited by 11
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
|Journal of Clinical Oncology|2000|383
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
|Supportive Care in Cancer|2013|182
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
|Clinical Cancer Research|2007|123
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
|Journal of Bone and Mineral Research|2009|120